(Q39062455)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

8 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216. (English)

1 reference

8 September 2017

1 reference

Marlena Walls

1

1 reference

8 September 2017

Sangita M Baxi

2

1 reference

8 September 2017

Pramod P Mehta

3

1 reference

8 September 2017

Kevin K-C Liu

4

1 reference

8 September 2017

Jinjiang Zhu

5

1 reference

8 September 2017

Heather Estrella

6

1 reference

8 September 2017

Chunze Li

7

1 reference

8 September 2017

Michael Zientek

8

1 reference

8 September 2017

Qing Zong

9

1 reference

8 September 2017

Tod Smeal

10

1 reference

8 September 2017

Min-Jean Yin

11

1 reference

8 September 2017

language of work or name

English

0 references

publication date

15 November 2013

1 reference

8 September 2017

Clinical Cancer Research

1 reference

8 September 2017

20

1 reference

8 September 2017

631-643

1 reference

8 September 2017

3

1 reference

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

8 September 2017

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE11003

Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Signalling by PI3K isoforms: insights from gene-targeted mice.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

mTOR, cancer and transplantation.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Small-cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

The molecular pathogenesis of small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

AKT/PKB signaling: navigating downstream

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

PI3K pathway alterations in cancer: variations on a theme

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Essential role for nuclear PTEN in maintaining chromosomal integrity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Perturbations of the AKT signaling pathway in human cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Defining the role of mTOR in cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Structural basis for activation and inhibition of class I phosphoinositide 3-kinases

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Small cell lung cancer: new clinical recommendations and current status of biomarker assessment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Endogenous viruses: insights into viral evolution and impact on host biology

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Update on new drugs in small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Bim: a novel member of the Bcl-2 family that promotes apoptosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Regulation of glucose transport by insulin: traffic control of GLUT4.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

PI3K/Akt: getting it right matters

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

The functions and regulation of the PTEN tumour suppressor

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Activation of phosphatidylinositol 3-kinase by insulin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Targeting the mTOR pathway in tumor malignancy.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

PTEN: from pathology to biology

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Phosphatidylinositol 3-kinase: the oncoprotein

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-13-1663

Identifiers

DOI

10.1158/1078-0432.CCR-13-1663

1 reference

8 September 2017

1 reference